Drug Manufacturers - Specialty & Generic
Compare Stocks
5 / 10Stock Comparison
SXTC vs TCMD vs LNTH vs SBFM vs MDT
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Drug Manufacturers - Specialty & Generic
Drug Manufacturers - Specialty & Generic
Medical - Devices
SXTC vs TCMD vs LNTH vs SBFM vs MDT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Medical - Devices | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Medical - Devices |
| Market Cap | $671K | $579M | $6.06B | $737K | $97.62B |
| Revenue (TTM) | $2M | $344M | $1.55B | $36M | $35.48B |
| Net Income (TTM) | $-3M | $20M | $279M | $-6M | $4.61B |
| Gross Margin | 21.1% | 75.7% | 60.5% | 33.3% | 61.9% |
| Operating Margin | -154.0% | 9.4% | 18.8% | -17.9% | 17.9% |
| Forward P/E | — | 22.5x | 17.7x | — | 13.8x |
| Total Debt | $984K | $16M | $738K | $952K | $28.52B |
| Cash & Equiv. | $18M | $83M | $359M | $10M | $2.22B |
SXTC vs TCMD vs LNTH vs SBFM vs MDT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| China SXT Pharmaceu… (SXTC) | 100 | 0.0 | -100.0% |
| Tactile Systems Tec… (TCMD) | 100 | 52.9 | -47.1% |
| Lantheus Holdings, … (LNTH) | 100 | 677.8 | +577.8% |
| Sunshine Biopharma,… (SBFM) | 100 | 0.6 | -99.4% |
| Medtronic plc (MDT) | 100 | 77.2 | -22.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SXTC vs TCMD vs LNTH vs SBFM vs MDT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Among these 5 stocks, SXTC doesn't own a clear edge in any measured category.
TCMD is the #2 pick in this set and the best alternative if defensive is your priority.
- Beta 0.86, current ratio 4.03x
- +163.6% vs SXTC's -99.4%
LNTH ranks third and is worth considering specifically for long-term compounding and sleep-well-at-night.
- 42.9% 10Y total return vs TCMD's 131.5%
- Lower volatility, beta 0.45, Low D/E 0.1%, current ratio 2.70x
- 18.0% margin vs SXTC's -189.8%
SBFM is the clearest fit if your priority is growth exposure.
- Rev growth 44.7%, EPS growth 97.9%, 3Y rev CAGR 434.5%
- 44.7% revenue growth vs SXTC's -9.7%
MDT carries the broadest edge in this set and is the clearest fit for income & stability.
- Dividend streak 36 yrs, beta 0.42, yield 3.7%
- Better valuation composite
- Beta 0.42 vs SBFM's 1.33
- 3.7% yield; 36-year raise streak; the other 4 pay no meaningful dividend
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 44.7% revenue growth vs SXTC's -9.7% | |
| Value | Better valuation composite | |
| Quality / Margins | 18.0% margin vs SXTC's -189.8% | |
| Stability / Safety | Beta 0.42 vs SBFM's 1.33 | |
| Dividends | 3.7% yield; 36-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +163.6% vs SXTC's -99.4% | |
| Efficiency (ROA) | 175.8% ROA vs SBFM's -19.7%, ROIC 6.0% vs -42.9% |
SXTC vs TCMD vs LNTH vs SBFM vs MDT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
SXTC vs TCMD vs LNTH vs SBFM vs MDT — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
LNTH leads in 2 of 6 categories
MDT leads 1 • SXTC leads 0 • TCMD leads 0 • SBFM leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
LNTH leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MDT is the larger business by revenue, generating $35.5B annually — 20382.5x SXTC's $2M. LNTH is the more profitable business, keeping 18.0% of every revenue dollar as net income compared to SXTC's -189.8%. On growth, TCMD holds the edge at +22.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $2M | $344M | $1.5B | $36M | $35.5B |
| EBITDAEarnings before interest/tax | -$3M | $39M | $347M | -$6M | $9.4B |
| Net IncomeAfter-tax profit | -$3M | $20M | $279M | -$6M | $4.6B |
| Free Cash FlowCash after capex | -$2M | $39M | $372M | -$9M | $5.4B |
| Gross MarginGross profit ÷ Revenue | +21.1% | +75.7% | +60.5% | +33.3% | +61.9% |
| Operating MarginEBIT ÷ Revenue | -154.0% | +9.4% | +18.8% | -17.9% | +17.9% |
| Net MarginNet income ÷ Revenue | -189.8% | +5.9% | +18.0% | -17.4% | +13.0% |
| FCF MarginFCF ÷ Revenue | -134.8% | +11.4% | +24.0% | -26.1% | +15.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | -7.8% | +22.8% | +1.2% | +1.2% | +8.8% |
| EPS Growth (YoY)Latest quarter vs prior year | -119.1% | +38.5% | +76.5% | +21.5% | -11.9% |
Valuation Metrics
Evenly matched — SBFM and MDT each lead in 2 of 6 comparable metrics.
Valuation Metrics
At 21.1x trailing earnings, MDT trades at a 33% valuation discount to TCMD's 31.3x P/E. On an enterprise value basis, MDT's 14.1x EV/EBITDA is more attractive than LNTH's 15.0x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $670,507 | $579M | $6.1B | $736,836 | $97.6B |
| Enterprise ValueMkt cap + debt − cash | -$16M | $511M | $5.7B | -$8M | $123.9B |
| Trailing P/EPrice ÷ TTM EPS | -0.20x | 31.28x | 27.29x | -0.14x | 21.09x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 22.55x | 17.70x | — | 13.80x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 35.17x |
| EV / EBITDAEnterprise value multiple | — | 14.23x | 14.96x | — | 14.06x |
| Price / SalesMarket cap ÷ Revenue | 0.39x | 1.76x | 3.93x | 0.02x | 2.91x |
| Price / BookPrice ÷ Book value/share | 0.04x | 2.73x | 5.84x | 0.03x | 2.04x |
| Price / FCFMarket cap ÷ FCF | — | 14.31x | 17.11x | — | 18.83x |
Profitability & Efficiency
LNTH leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
LNTH delivers a 24.3% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-25 for SBFM. LNTH carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to MDT's 0.59x. On the Piotroski fundamental quality scale (0–9), TCMD scores 8/9 vs SBFM's 1/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -21.4% | +9.7% | +24.3% | -24.6% | +9.4% |
| ROA (TTM)Return on assets | -15.2% | +7.5% | +12.4% | -19.7% | +175.8% |
| ROICReturn on invested capital | -142.0% | +13.8% | +30.6% | -42.9% | +6.0% |
| ROCEReturn on capital employed | -17.9% | +11.9% | +17.1% | -25.2% | +7.5% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 8 | 5 | 1 | 6 |
| Debt / EquityFinancial leverage | 0.06x | 0.07x | 0.00x | 0.04x | 0.59x |
| Net DebtTotal debt minus cash | -$17M | -$67M | -$358M | -$9M | $26.3B |
| Cash & Equiv.Liquid assets | $18M | $83M | $359M | $10M | $2.2B |
| Total DebtShort + long-term debt | $983,877 | $16M | $738,000 | $952,480 | $28.5B |
| Interest CoverageEBIT ÷ Interest expense | -4.14x | 76.34x | 15.83x | -757.53x | 9.08x |
Total Returns (Dividends Reinvested)
Evenly matched — TCMD and LNTH each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LNTH five years ago would be worth $43,814 today (with dividends reinvested), compared to $1 for SBFM. Over the past 12 months, TCMD leads with a +163.6% total return vs SXTC's -99.4%. The 3-year compound annual growth rate (CAGR) favors TCMD at 11.0% vs SBFM's -89.9% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -99.4% | -6.4% | +38.3% | -18.0% | -20.0% |
| 1-Year ReturnPast 12 months | -99.4% | +163.6% | +15.7% | -14.6% | -5.5% |
| 3-Year ReturnCumulative with dividends | -99.8% | +36.9% | -1.9% | -99.9% | -6.3% |
| 5-Year ReturnCumulative with dividends | -100.0% | -53.3% | +338.1% | -100.0% | -29.2% |
| 10-Year ReturnCumulative with dividends | -100.0% | +131.5% | +4289.6% | -100.0% | +24.3% |
| CAGR (3Y)Annualised 3-year return | -87.6% | +11.0% | -0.6% | -89.9% | -2.1% |
Risk & Volatility
Evenly matched — LNTH and MDT each lead in 1 of 2 comparable metrics.
Risk & Volatility
MDT is the less volatile stock with a 0.42 beta — it tends to amplify market swings less than SBFM's 1.33 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LNTH currently trades 98.1% from its 52-week high vs SXTC's 0.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.19x | 0.86x | 0.45x | 1.33x | 0.42x |
| 52-Week HighHighest price in past year | $1046.98 | $37.75 | $94.86 | $2.43 | $106.33 |
| 52-Week LowLowest price in past year | $0.08 | $9.34 | $47.25 | $0.95 | $75.91 |
| % of 52W HighCurrent price vs 52-week peak | +0.2% | +67.9% | +98.1% | +43.2% | +71.6% |
| RSI (14)Momentum oscillator 0–100 | 29.3 | 57.6 | 69.9 | 56.2 | 29.2 |
| Avg Volume (50D)Average daily shares traded | 53K | 279K | 872K | 37K | 7.9M |
Analyst Outlook
MDT leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: TCMD as "Buy", LNTH as "Buy", MDT as "Buy". Consensus price targets imply 53.0% upside for TCMD (target: $39) vs 6.7% for LNTH (target: $99). MDT is the only dividend payer here at 3.65% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | — | Buy |
| Price TargetConsensus 12-month target | — | $39.25 | $99.25 | — | $109.50 |
| # AnalystsCovering analysts | — | 11 | 17 | — | 49 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +3.7% |
| Dividend StreakConsecutive years of raises | — | 1 | 0 | — | 36 |
| Dividend / ShareAnnual DPS | — | — | — | — | $2.78 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +4.6% | +5.0% | +100.0% | +3.3% |
LNTH leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MDT leads in 1 (Analyst Outlook). 3 tied.
SXTC vs TCMD vs LNTH vs SBFM vs MDT: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SXTC or TCMD or LNTH or SBFM or MDT a better buy right now?
For growth investors, Sunshine Biopharma, Inc.
(SBFM) is the stronger pick with 44. 7% revenue growth year-over-year, versus -9. 7% for China SXT Pharmaceuticals, Inc. (SXTC). Medtronic plc (MDT) offers the better valuation at 21. 1x trailing P/E (13. 8x forward), making it the more compelling value choice. Analysts rate Tactile Systems Technology, Inc. (TCMD) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SXTC or TCMD or LNTH or SBFM or MDT?
On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.
1x versus Tactile Systems Technology, Inc. at 31. 3x. On forward P/E, Medtronic plc is actually cheaper at 13. 8x.
03Which is the better long-term investment — SXTC or TCMD or LNTH or SBFM or MDT?
Over the past 5 years, Lantheus Holdings, Inc.
(LNTH) delivered a total return of +338. 1%, compared to -100. 0% for Sunshine Biopharma, Inc. (SBFM). Over 10 years, the gap is even starker: LNTH returned +42. 9% versus SBFM's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SXTC or TCMD or LNTH or SBFM or MDT?
By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.
42β versus Sunshine Biopharma, Inc. 's 1. 33β — meaning SBFM is approximately 213% more volatile than MDT relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 59% for Medtronic plc — giving it more financial flexibility in a downturn.
05Which is growing faster — SXTC or TCMD or LNTH or SBFM or MDT?
By revenue growth (latest reported year), Sunshine Biopharma, Inc.
(SBFM) is pulling ahead at 44. 7% versus -9. 7% for China SXT Pharmaceuticals, Inc. (SXTC). On earnings-per-share growth, the picture is similar: Sunshine Biopharma, Inc. grew EPS 97. 9% year-over-year, compared to -129. 1% for China SXT Pharmaceuticals, Inc.. Over a 3-year CAGR, SBFM leads at 434. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SXTC or TCMD or LNTH or SBFM or MDT?
Lantheus Holdings, Inc.
(LNTH) is the more profitable company, earning 15. 2% net margin versus -189. 8% for China SXT Pharmaceuticals, Inc. — meaning it keeps 15. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LNTH leads at 20. 2% versus -154. 0% for SXTC. At the gross margin level — before operating expenses — TCMD leads at 75. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SXTC or TCMD or LNTH or SBFM or MDT more undervalued right now?
On forward earnings alone, Medtronic plc (MDT) trades at 13.
8x forward P/E versus 22. 5x for Tactile Systems Technology, Inc. — 8. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TCMD: 53. 0% to $39. 25.
08Which pays a better dividend — SXTC or TCMD or LNTH or SBFM or MDT?
In this comparison, MDT (3.
7% yield) pays a dividend. SXTC, TCMD, LNTH, SBFM do not pay a meaningful dividend and should not be held primarily for income.
09Is SXTC or TCMD or LNTH or SBFM or MDT better for a retirement portfolio?
For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
42), 3. 7% yield). Both have compounded well over 10 years (MDT: +24. 3%, SBFM: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SXTC and TCMD and LNTH and SBFM and MDT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SXTC is a small-cap quality compounder stock; TCMD is a small-cap quality compounder stock; LNTH is a small-cap quality compounder stock; SBFM is a small-cap high-growth stock; MDT is a mid-cap income-oriented stock. MDT pays a dividend while SXTC, TCMD, LNTH, SBFM do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.